Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6270984
Modulating robo: ligand interactions
expired -
US 6270747
In vitro and in vivo assay for agents which treat mucus hypersecretion
expired -
US 6270979
Methods for anti-addictive narcotic analgesic treatments
expired -
US 6270775
Streptococcal C5a peptidase vaccine
expired -
US 6268347
Prosaposin-derived peptides
expired -
US 6268194
IKB kinase and methods of using same
expired -
US 6268352
Promoters of neural regeneration
expired -
US 6268348
Synthetic compounds and compositions with enhanced cell binding
expired -
US 6267960
PSCA: prostate stem cell antigen
expired -
US 6265214
Methods and compositions for inducing monocyte cytotoxicity
expired -
US 6265192
Glycosly sulfortransferase-3
expired -
US 6264952
Method for protecting a mammalian host against infection by Brucella
expired -
US 6266622
Nuclear receptor ligands and ligand binding domains
expired -
US 6265175
Method for production of neuroblasts
expired -
US 6265563
Opioid receptor genes
expired -
US 6265539
Prophylaxis and therapy of acquired immunodeficiency syndrome
expired -
US 6262242
Tumor suppressor designated TS10Q23.3
expired -
US 6262335
Transgenic mice expressing APP mutant at amino acids 717, 721 and 722
expired -
US 6262244
DNA and amino acid sequence specific for natural killer cells
expired -
US 6262257
Calixpyrroles, calixpyridinopyrroles and calixpyridines
expired -
US 6262235
Leptospiral outer membranes protein, LipL46
expired -
US 6261791
Method for diagnosing cancer using specific PSCA antibodies
expired -
US 6261836
Telomerase
expired -
US 6261535
Diagnostic methods for targeting the vasculature of solid tumors
expired -
US 6261789
Methods for detecting the presence of a PSCA protein using PSCA antibodies
expired -
US 6258939
PSCA antibodies and hybridomas producing them
expired -
US 6258870
Gels for encapsulation of biological materials
expired -
US 6258845
DFMO and sulindac combination in cancer chemoprevention
expired -
US 6258789
Delivery of gene products by intestinal cell expression
expired -
US 6255091
Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
expired -
US 6254869
Cryptopain vaccines, antibodies, proteins, peptides, DNA and RNA for prophylaxis, treatment and diagnosis and for detection of cryptosporidium species
expired -
US 6254865
Method of treating huntington's disease using HNT neurons
expired -
US 6255289
Gene delivery by secretory gland expression
expired -
US 6255485
Purine inhibitors of protein kinases, G proteins and polymerases
expired -
US 6255519
Radioiodinated phospholipid ether analogs and methods of using the same
expired -
US 6255336
Amino ceramide-like compounds and therapeutic methods of use
expired -
US 6251878
Inhibition of UV-induced immune suppression and interleukin-10 production by cytoprotective tamarind oligosaccharides
expired -
US 6251871
P16 expression constructs and their application in cancer therapy
expired -
US 6251362
Method of establishing the optimal radiation dose
expired -
US 6251903
Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist
expired -
US 6252093
Total synthesis of antitumor acylfulvenes
expired -
US 6248351
Human PEA3 is a tumor suppressor for cancer cells
expired -
US 6248788
Therapeutic method with capsaicin and capasicin analogs
expired -
US 6248916
Macromolecular structures for boron neutron-capture therapy
expired -
US 6248528
Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
expired -
US 6245747
Targeted site specific antisense oligodeoxynucleotide delivery method
expired -
US 6245512
Promoter for VEGF receptor
expired -
US 6245561
.beta.-alethine use in cell culture and therapy
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory